Emet Surgical Opens Crowdsourced Investment Round via StartEngine
Emet Surgical, developers of innovative tools to improve surgery outcomes, today announced that it has opened its StartEngine share offering that will help the company reach its goal of enhancing cancer patient surgery outcomes while providing improved ROI for healthcare providers and insurers.
The company intends to use the net proceeds from its StartEngine offering to purchase components and contract manufacturing services needed for product production, fund research and development efforts, and cover the costs associated with patent applications and FDA approval, among others, all in accordance with the company's general business plans and goals. Participants in the StartEngine campaign will be among the first investors of a pioneering medical technology company that is part of an estimated $536.12 billion global medical device market.
StartEngine is the leading equity crowdfunding platform. The company has hosted over 1,000 successful funding rounds between Reg. CF and Reg. A
Emet Surgical's progress to this point has been aided by its membership in the Colorado BioScience Association (CBSA), and participation in Startup Nation Central finder business platform, Israeli NGO promoting Israeli innovation around the world. Both organizations have provided guidance and enabled connections that set Emet Surgical apart from its competitors and other early-stage startups.
Emet Surgical has emerged as a leader in developing cutting-edge surgical solutions that empower healthcare professionals and enhance the quality of patient care. In consultation with medical professionals in the US and Israel, the company has developed solutions that serve as the foundation for more efficient and effective surgeon and pathologist communication.
TrueMargintm is an easy-to-use tumor margin-marking system that requires no new tools and no new training for surgeons and can be simply added to the surgical and pathology workflows. TrueMargin overcomes conventional tumor marking that is often incomplete by providing specific in-vivo and ex-vivo location and orientation details. Emet Surgical's goal for TrueMargin is to secure FDA 510(k) clearance as well as other country registrations with volume production and distribution starting 60 days after clearance.
TrueGastrotm is a highly visible method of marking the colon for surveillance and surgery. TrueGastro is intended to replace outdated and risky marking techniques made ineffective with the shift from open to minimally invasive colon cancer surgeries. TrueGastro is now in the final engineering phase and testing is anticipated to begin later this year.
"Tumor and structure marking tools currently available do not meet today's needs nor are keeping pace with advanced surgical techniques," said Witkow. "Emet Surgical is aiming to improve cancer surgery outcomes by offering innovative tools that enable collaboration between surgeons and other medical specialists who are involved in the patients care. But we can't do it alone. We believe StartEngine will engage investors who appreciate our product goals and investment opportunity. By participating in our StartEngine offering, investors will have an opportunity to get in on the ground floor of a revolutionary offering aiming to improve cancer patient outcomes while empowering surgeons to achieve better outcomes and reduce treatment costs."
Emet Surgical's assets consist of intellectual property applications and grants, product designs and the engineering and manufacturing drawings and work plans needed to manufacture products. Its quality and regulatory consultant developed a custom quality management system necessary to support the requirements of US and European Union medical device regulatory bodies. Six thousand product samples have been produced proving the plans and testing of the company's TrueMargintm products at independent labs along with their documentation have been submitted to the US FDA in the form of an application for 510(k) clearance. The company has filed applications for two provisional utility patents and two design patents.
Those interested in reserving a spot in the StartEngine funding round can visit https://www.startengine.com/offering/emetsurgical
About Emet Surgical
Taking its name from the Hebrew word for "truth," Emet Surgical is enabling true surgeon/pathologist collaboration. Emet Surgical's TrueMargintm tumor margin marking tools, now under regulatory review, provide surgeons and pathologists with specific in-vivo and ex-vivo tumor margin, location, and orientation details. TrueMargin tools for open, minimally invasive, and robotic procedures enable communication and collaboration not seen before. Founded in 2022, the company is headquartered in Denver with significant operations in Tel Aviv and Haifa, Israel. Additional information is available at www.EmetSurgical.com or by emailing [email protected].
News published on and distributed by:
